Biopharma Daily Updates - 12/15/20

$XBI $146.32 (+0.2%)

Data Updates:

$ATNX (-6%) - FDA approval of Klisyri (Tirbanibulin)

https://ir.athenex.com/news-releases/news-release-details/athenex-announces-fda-approval-klisyrir-tirbanibulin-treatment


$KNSA (+0.5%) - Start enrollment in ph2b of Vixarelimab

https://investors.kiniksa.com/news-releases/news-release-details/kiniksa-commences-dosing-vixarelimab-phase-2b-clinical-trial


$NKTR (+4.5%) - Dosing underway in ph1/2 of NKTR-255 + Cetuximab

https://ir.nektar.com/news-releases/news-release-details/nektar-therapeutics-announces-dosing-first-patients-phase-12


$GILD (-0.5%) + $GLPG (-1%) - Agreement for Jyseleca (Filgotinib)

http://investors.gilead.com/news-releases/news-release-details/gilead-and-galapagos-announce-new-commercialization-and


$RDUS (+5%) - Tymlos sales update

https://ir.radiuspharm.com/news-releases/news-release-details/radius-health-inc-provides-business-update


Financial Updates

$PHAT (+13%) - Public offering

$TGTX (+17%) - Prices offering at $43.50/share

$MIRM (-23%) - Prices offering at $20/share



0 comments